Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
To seek the efficacy signals of trastuzumab in combination with chemotherapy in pretreated
patients of HER2 positive, relapse or metastatic carcinoma of digestive system as response
rate (RR) determined by the Investigator using RECIST 1.1, and provide evidence for phase III
clinical trial.